|Study title||Cell type (product name)||Sponsor/collaborator||Trial location||Disease||Stage of trial||Cell delivery||Status of trial||Registration number||Estimated or actual study completion date||Note/reference|
|A. Eye disease|
|Safety and Tolerability of Sub-retinal Transplantation of hESC-Derived RPE (MA09-hRPE) Cells in Patients with Advanced Dry Age-Related Macular Degeneration (Dry AMD)||hESC-derived RPE
|Astellas Institute for Regenerative Medicine||United States||Dry AMD||Phase I/II||Cell suspension||Completed||NCT01344993||August 1, 2015||< Progress reports > Lancet. 2015 Feb 7;385(9967):509-16.
Lancet. 2012 Feb 25;379(9817):713-20.
< Follow-up study > Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFc1-9.
|Sub-retinal transplantation of hESC-derived RPE (MA09-hRPE) cells in patients with SMD||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United States||Stargardt’s macular dystrophy (SMD)||Phase I/II||Cell suspension||Completed||NCT01345006||August 1, 2015|
|Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United States||Stargardt’s macular dystrophy (SMD)||Phase I/II||Cell suspension||Active, not recruiting||NCT02445612||December 1, 2019||Follow-up study for NCT1345006|
|Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United States||Dry AMD||Phase I/II||Cell suspension||Active, not recruiting||NCT02463344||December 1, 2019||Follow-up study for NCT1344993|
|Safety and tolerability of sub-retinal transplantation of hESC-RPE cells in patients with SMD||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United Kingdom||Stargardt’s macular dystrophy (SMD)||Phase I/II||Cell suspension||Completed||NCT01469832||September 1, 2015||< Progress reports > Ophthalmology. 2018
|A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United Kingdom||Stargardt’s macular dystrophy (SMD)||Phase I/II||Cell suspension||Active, not recruiting||NCT02941991||December 1, 2019||Follow-up study for NCT1469832|
|A Phase 1b Dose Escalation Evaluation of Safety and Tolerability and a Phase 2 Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration||hESC-derived RPE (ASP7317)||Astellas Institute for Regenerative Medicine||United States||AMD||Phase I/II||Cell suspension||Recruiting||NCT03178149||October 1, 2026||Clinical study of ASP7317, a new cell line to replace MA09-Hrpe|
|A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration (AMD)||hESC-derived RPE (MA09-hRPE)||CHABiotech (licensed from Astellas Institute)||Korea||Dry AMD||Phase I/II||Cell suspension||Unknown||NCT01674829||April 1, 2016||< Progress report > Stem Cell Reports. 2015 May 12;4(5):860-72.
< Progress report of NCT01674829 > JAMA Ophthalmol. 2017 Mar 1;135(3):287-289.
|Safety and Tolerability of MA09-hRPE Cells in Patients with Stargardt’s Macular Dystrophy (SMD)||hESC-derived RPE (MA09-hRPE)||CHABiotech (licensed from Astellas Institute)||Korea||Stargardt's macular dystrophy (SMD)||Phase I||Cell suspension||Unknown||NCT01625559||June 1, 2015|
|A study of implantation of RPE in subjects with acute wet age-related macular degeneration||hESC-derived RPE (PF-05206388)||Pfizer/University College, London||United Kingdom||Wet AMD||Phase I||Membrane-immobilized monolayer sheet||Active, not recruiting||NCT01691261||December 1, 2019||< Progress report including nonclinical and clinical studies > Nat Biotechnol. 2018 Mar 19. doi: 10.1038/nbt.4114.|
|Retinal Pigment Epithelium Safety Study For Patients In B4711001||hESC-derived RPE (PF-05206388)||Pfizer||United Kingdom||Wet AMD||Phase I||Membrane-immobilized monolayer sheet||Active, not recruiting||NCT03102138||October 4, 2020||Follow-up study for NCT01691261|
|Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration||hESC-derived RPE (OpRegen)||Lineage Cell Therapeutics (former BioTime)/Cell Cure Neurosciences||United States and Israel||Dry AMD||Phase I/II||Cell suspension||Recruiting||NCT02286089||December 1, 2024||https://lineagecell.com/products-pipeline/opregen/
< Nonclinical study > Transl Vis Sci Technol. 2017 Jun; 6(3): 17
|Study of subretinal implantation of human ESC-derived RPE cells in advanced dry AMD||hESC-derived RPE (CPCB-RPE1)||Regenerative Patch Technologies||United States||Dry AMD/geographic Atrophy||Phase I/II||Membrane- immobilized monolayer sheet||Active, not recruiting||NCT02590692||June 1, 2023||< Nonclinical study > Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1553-65.
< Progress report of clinical study (phase I/II) > Science Translational Medicine 04 Apr 2018: Vol. 10, Issue 435, eaao4097
|Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases||hESC-derived RPE||Southwest Hospital||China||AMD and Stargardt||Phase I/II||Cell suspension||Active, not recruiting||NCT02749734||December 1, 2019||No available information|
|Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases||hESC-derived RPE||Chinese Academy of Sciences/Beijing Tongren Hospital||China||Dry AMD||Phase I/II||Cell suspension||Recruiting||NCT02755428||December 1, 2019||No available information|
|Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells||hESC-derived RPE||Chinese Academy of Sciences/The First Affiliated Hospital of Zhengzhou University||China||Dry AMD||Phase I/II||Cell suspension||Recruiting||NCT03046407||December 1, 2020||No available information|
|Stem Cell Therapy for Outer Retinal Degenerations||hESC-derived RPE||Federal University of São Paulo||Brazil||Dry AMD/wet AMD/Stargardt||Phase I/II||Cell suspension or monolayer in a polymeric substrate||Unknown||NCT02903576||June 1, 2019||No available information|
|A Safety surveillance study in subjects with macular degenerative disease treated with human ESC-derived retinal pigment epithelial cell therapy||hESC-derived RPE (MA09-hRPE)||Astellas Institute for Regenerative Medicine||United States||Macular degeneration||Phase I/II||Cell suspension||Enrolling by invitation||NCT03167203||December 1, 2029||A long-term (up to 15 years) safety surveillance study|
|Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa||hESC-derived RPE||Qi Zhou/Beijing Tongren Hospital||China||Retinitis pigmentosa||Phase I||-||Recruiting||NCT03944239||December 1, 2020||No available information|
|Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation||hESC-derived RPE||Centre d'Etude des Cellules Souches||France||Retinitis pigmentosa (due to monogenic mutation)||Phase I/II||-||Recruiting||NCT03963154||December 15, 2021||No available information|
|B. Other disease|
|Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure (ESCORT)||hESC-derived CD15+ Isl-1+ cardiac progenitors||Assistance publique, Hôpitaux de Paris||France||Severe heart failure||Phase I||Cells embedded in fibrin patch||Completed||NCT02057900||March 22, 2018||< Nonclinical study > Eur Heart J. 2015 Mar 21;36(12):743-50.
< Progress reports of clinical study >
Eur Heart J. 2015 Aug 7;36(30):2011-7.
J Am Coll Cardiol. 2018 Jan 30;71(4):429-438.
|A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus||hESC-derived pancreatic precursor cells (VC-01™ combination product)||ViaCyte/California Institute for Regenerative Medicine (CIRM)||United States/Canada||Type 1 diabetes||Phase I/II||PEC-01 cells encapsulated in a medical device||Active, not recruiting||NCT02239354||January 1, 2021||VC-01™, a combination product (PEC-01™ cells + Encaptra® DDS) (see PMID: 29369575)
|One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™||hESC-derived pancreatic precursor cells (VC-01™ combination product)||ViaCyte||United States||Type 1 diabetes||Observational study||PEC-01 cells encapsulated in a medical device||Enrolling by invitation||NCT02939118||November 1, 2021||VC-01™ (PEC-Encap™) delivers the PEC-01 pancreatic progenitor cells in a immunoprotective device
|A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus||hESC-derived pancreatic precursor cells (VC-02™ combination product, aka PEC-Direct)||ViaCyte||Canada||Type 1 diabetes||Phase I||PEC-01 cells loaded into a delivery device||Completed||NCT03162926||February 15, 2018||VC-02™ (PEC-Direct™) delivers the PEC-01 pancreatic progenitor cells in a non-immunoprotective device
|A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness||hESC-derived pancreatic precursor cells (VC-02™ combination product, aka PEC-Direct)||ViaCyte||United States||Type 1 diabetes||Phase I/II||PEC-01 cells loaded into a delivery device||Recruiting||NCT03163511||March 1, 2022|
|Safety Study of GRNOPC1 in Spinal Cord Injury||hESC-derived oligodendrocyte progenitors (GRNOPC1/AST-OPC1)||Asterias Biotherapeutics||United States||Spinal cord injury||Phase I||Cell suspension||Completed (took over from Geron)||NCT01217008||July 1, 2013||< Nonclinical study > Regen Med. 2015 Nov;10(8):939-58.|
|Dose Escalation Study of AST-OPC1 in Spinal Cord Injury||hESC-derived oligodendrocyte progenitors (AST-OPC1)||Asterias Biotherapeutics||United States||Spinal cord injury||Phase I/II||Cell suspension||Completed||NCT02302157||December 1, 2018||https://www.cirm.ca.gov/our-progress/awards/phase-iiia-dose-escalation-safety-study-ast-opc1-patients-cervical-sensorimotor (You can check progress report on the trial)|
|A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease||Human parthenogenetic stem cell-derived neural stem cells(ISC-hpNSC)||Cyto Therapeutics/International Stem Cell Corporation||Australia||Parkinson's disease||Phase I||Cell suspension||Active, not recruiting||NCT02452723||June 1, 2020||< Nonclinical study > Sci Rep. 2016 Sep 30;6:34478.|
|Safety and Efficacy Study of Human ESC-Derived Neural Precursor Cells in the Treatment of Parkinson’s Disease||Human embryonic stem cells-derived neural precursor cells||Chinese Academy of Sciences/The First Affiliated Hospital of Zhengzhou University||China||Parkinson's Disease||Phase I/II||Cell suspension||Recruiting||NCT03119636||December 1, 2020||< Nonclinical study > Stem Cell Reports. 2018 Jul 10;11(1):171-182.|
|A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)||Astrocytes derived from human embryonic stem cells (AstroRx)||Kadimastem||Israel||ALS (amyotrophic lateral sclerosis)||Phase I/II||Cell suspension||Recruiting||NCT03482050||August 1, 2020||< Nonclinical study > Stem Cell Res Ther. 2018; 9: 152.|
|Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury||hESC-derived MSC-like cell||Tongji Hospital/Chinese Academy of Sciences||China||Meniscus injury||Phase I||-||Active, not recruiting||NCT03839238||September 30, 2020||No available information|